No More Waiting: 340B Drug Pricing Program Pharma Oversight and Enforcement Rule To Be Effective January 1, 2019

December 17, 2018 Alerts and Newsletters

The U.S. Department of Health and Human Services ("HHS") recently published a final rule on the 340B Drug Pricing Program ("340B Program"), moving the effective date for changes to the program up to January 1, 2019. Making the rule effective next month is welcome news for eligible hospitals, clinics, and health centers that serve vulnerable populations ("Covered Entities") because it establishes the methodologies for pharmaceutical manufacturers' 340B ceiling prices as well as establishes civil monetary penalties ("CMPs") for manufacturers that knowingly and intentionally charge Covered Entities more than the designated ceiling price. HHS is also planning on launching a website where Covered Entities may easily verify manufacturer pricing data to ensure that they are not being overcharged. The website is expected to open during the first quarter of 2019.

Background

The 340B Program requires drug manufacturers who want to participate in Medicaid to provide outpatient drugs at a 20%-50% discount to Covered Entities. In January 2017, HHS published a final rule ("2017 Rule") in the Federal Registerin which it set forth the calculation of the 340B ceiling prices, created the penny pricing policy, and established CMPs. Now after eight years and five delays, each Covered Entity will be able to ensure that manufacturers are observing the drug price ceilings and HHS will be able to enforce them.

The 2017 Rule will apply to all drug manufacturers that are required to make their drugs available to Covered Entities under the 340B Program. Since Covered Entities get reimbursed from the government at a higher rate than what they are charged, the 340B Program plays an integral role in helping providers provide high-quality and low-cost care to patients that otherwise would not have the ability to pay for their care. Below, we highlight some of the key provisions from the 2017 Rule.


Ceiling Price

HHS receives both the average manufacturer price and unit rebate amount quarterly data from the Centers for Medicare & Medicaid Services to calculate the 340B ceiling price. Unfortunately, the Office of the Inspector General ("OIG") has found that drug manufacturers oftentimes do not accurately provide the required discounts to Covered Entities.
Created to discourage drug manufactures from raising prices faster than inflation, the penny pricing policy mandates a manufacturer to charge Covered Entities $0.01 per unit if the 340B ceiling price equals zero. An OIG report discovered drug manufacturers commonly overcharging Covered Entities for drugs that would be covered under the penny pricing policy. These Covered Entities paid an excess from $1.65 to $1,931 over the ceiling price.


Manufacturer CMPs

Drug manufacturers that knowingly and intentionally charge Covered Entities a price for a 340B drug that exceeds the price ceiling will face CMPs. The 2017 Rule directs drug manufacturers participating in the 340B Program to disclose the maximum per unit ceiling price that can be charged to 340B Covered Entities. Enforcement will be maintained through a closed website available to 340B participating providers. Federal regulators will post drug pricing information on the site.


Covered Entities Should be Vigilant

HHS has indicated that the ceiling price website will be launching soon. Hospitals and other Covered Entities are encouraged to follow the development of the online access and verify the ceiling prices they are charged by drug manufacturers to ensure that they are not being overcharged. Verrill Dana will continue to monitor and bring you updates on this matter.

For assistance with questions regarding the new implementation date, the 2017 Rule, or the 340B Program, please reach out to Gary Rosenberg or your regular Verrill Dana attorney.

Firm Highlights

Publication/Podcast

The Regulatory Sprint is Over - What’s at the Finish Line Under the New Stark and AKS Final Rules?

The U.S. Department of Health and Human Services (HHS) completed its “Regulatory Sprint” by finalizing changes to regulations pertaining to two federal fraud and abuse laws. On December 2, 2020, the Centers for Medicare...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

Matter

Common Rule

Guided multiple clients through the implementation of the revised HHS regulations (the "Common Rule"), including reviewing and revising policies and procedures, and assisting with institutional approaches to implementation.

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...

Publication/Podcast

Massachusetts Health Care Bill Makes Several Significant Changes

While you were celebrating the New Year, Governor Baker signed Chapter 260 of the Acts of 2020, an “Act promoting a resilient health care system that puts patients first,” the result of the Legislature’s...

Publication/Podcast

Fraud and Abuse Investigations Handbook for the Health Care Industry, Second Edition.

Health care attorney Paul Shaw co-authored Fraud and Abuse Investigations Handbook for the Health Care Industry, Second Edition with Robert Griffith, published by the American Health Law Association (AHLA). Paul and Robert provide legal...

News

Verrill Welcomes Health Care Attorney Alicia Siani

(February 2, 2021) – Verrill is pleased to welcome health care attorney Alicia Siani to the firm’s Boston, Massachusetts office. Siani represents clients in a wide range of regulatory issues, including HIPAA privacy matters...

Publication/Podcast

HHS Confirms Providers’ Right to 340B Discount Pricing for Contract Pharmacies

As a holiday gift to providers, the U.S. Department of Health and Human Services (HHS) General Counsel recently issued a strongly worded Advisory Opinion indicating that federal law requires drug manufacturers to deliver covered...

News

Verrill Welcomes Jeffrey A. Smagula, Experienced Health Care and Life Sciences Attorney, Former Health Plan Compliance Executive

(May 12, 2021) – Verrill is pleased to welcome Jeffrey A. Smagula to the firm’s Boston office as Counsel in its nationally recognized Health Care & Life Sciences Group. Jeff Smagula brings to Verrill...

Contact Verrill at (855) 307 0700